Zimmer Biomet Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Dodge & Cox reports a beneficial ownership of 24,124,735 shares, representing 12.5% of Zimmer Biomet Holdings, Inc. common stock as of June 30, 2026.
NYSE
Capital International Investors has reported a beneficial ownership of 6.4% in Zimmer Biomet Holdings, Inc., holding 12,438,366 shares.
NYSE
T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4.1% of Zimmer Biomet Holdings Inc. common stock as of March 31, 2026.
NYSE
Vanguard Capital Management has filed a Schedule 13G reporting a 7.54% beneficial ownership stake in Zimmer Biomet Holdings Inc.
NYSE
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Zimmer Biomet Holdings Inc. following an internal corporate realignment.
NYSE
Dodge & Cox, an investment adviser, has reported an increased passive beneficial ownership stake of 11.2% in Zimmer Biomet Holdings, Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: Dodge & Cox Discloses 10.2% Stake in Zimmer Biomet Holdings
Investment adviser Dodge & Cox has filed an amended Schedule 13G, disclosing a 10.2% beneficial ownership stake in Zimmer Biomet Holdings, Inc. as of April 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Schedule 13G, Disclosing 7.8% Passive Stake in Zimmer Biomet Holdings Inc.
BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, reporting a 7.8% beneficial ownership stake in Zimmer Biomet Holdings Inc. as of March 31, 2025, held for ordinary course of business purposes.
NYSE
Investment adviser Dodge & Cox has reported a 9.6% passive beneficial ownership stake in Zimmer Biomet Holdings, Inc. as of December 31, 2024.